Lilly Endowment Sells $176M in LLY Stock in Routine Transaction
ELI LILLY & Co
Subscribe to track LLY
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Lilly Endowment Sells $176M in LLY Stock in Routine Transaction
Company: ELI LILLY & Co (LLY) Form: 4 | Filed: 2025-11-20 Significance: Low
Insider: LILLY ENDOWMENT INC Relationship: 10% Owner
Transaction: • Type: Sale • Shares: 167,526 • Avg. Price: $1,051.25 • Value: $176,111,506 • Owned After: 92,644,452
Key Insight: Despite the large dollar value, this sale represents a negligible fraction (0.019%) of Eli Lilly's market cap and a tiny portion of the Endowment's total holdings, indicating a routine portfolio adjustment rather than a significant strategic shift.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: ELI LILLY & Co (LLY)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Lilly Endowment Inc., a major shareholder, sold $176.1 million worth of Eli Lilly stock, a transaction that is immaterial relative to the company's nearly trillion-dollar market capitalization and the Endowment's vast holdings.
- Market Impact: The sale is too small to have a meaningful impact on the stock, representing only 0.018% of shares outstanding.
Company Information
| Field | Value |
|---|---|
| Company | ELI LILLY & Co |
| Ticker Symbol | LLY |
| CIK | 0000059478 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | LILLY ENDOWMENT INC |
| CIK | 0000316011 |
| Title/Position | null |
| Relationship | 10% Owner |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-19 |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 167,526 |
| Price Per Share | $1,051.25 (Weighted Avg.) |
| Total Value | $176,111,506 |
| Shares Owned After | 92,644,452 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $176,111,506 |
| % of Market Cap | 0.019% |
| Shares Transacted | 167,526 |
| % of Shares Outstanding | 0.018% |
| Post-Transaction Ownership | 92,644,452 shares (9.79% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a mega-cap company like Eli Lilly with a market capitalization of $917.64 billion, a $176 million transaction is financially insignificant.
- Ownership Concentration: The sale represents a minuscule reduction (approx. 0.18%) in the Endowment's total position. Their ownership remains substantial at 9.79% of all outstanding shares, indicating continued long-term alignment.
- Transaction Significance: The sale falls well below the thresholds for moderate or high significance. It is likely part of the Endowment's regular, pre-planned diversification or liquidity generation strategy, as is common for large foundations.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction size is negligible compared to the company's market value and the stock's daily trading volume. It does not signal a change in the insider's fundamental outlook.
Volume & Sentiment
- Expected Volume Impact: Minimal. The number of shares is unlikely to cause a noticeable impact on trading volume.
- Sentiment Indicator: Neutral. This is a routine transaction by a large institutional holder, not a signal of changing sentiment.
Additional Context
Transaction Notes
- Special Circumstances: The sales occurred across multiple transactions at weighted average prices, as detailed in the filing's footnotes. This is typical for large block sales to minimize market impact.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
